Vaccination trial with the PBF-derived peptide in HLA-A24+ patients with osteosarcoma

Vaccination trial with the PBF-derived peptide in HLA-A24+ patients with osteosarcoma - Vaccination trial with the PBF-derived peptide in HLA-A24+ patients with osteosarcoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001633

Enrollment

Registered

2009-01-14

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteosarcoma

Interventions

HLA-A24-restricted PBF peptide (AYRPVSRNI) 1mg + IFA HLA-A24-restricted PBF peptide 10mg + IFA HLA-A24-restricted PBF peptide 1mg + IFA + Interferon alpha

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients are those (i) who have histologically confirmed unresectable osteosarcoma, (ii) who have PBF positive in tumor (assessed by RT-PCR or IHC), (iii) HLA-A*2402 positive, (iv) non-responder to chemotherapy or who could not receive further chemotherapy (iii) between 10 and 70 years old, (iv) ECOG performance status between 0 and 3, and (v) who gave informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria included (i) prior chemotherapy, steroid therapy, or other immunotherapy within the past 4 weeks, (ii) presence of severe organ failure or other cancers that might influence the prognosis, (iii) immunodeficiency or a history of splenectomy, (iv) severe cardiac insufficiency, acute infection, or hematopoietic failure, (v) pregnany or ongoing breast-feeding, (vi) unsuitability for the trial based on the clinical judgment of the doctors involved.

Design outcomes

Primary

Measure	Time frame
Toxicity, immunological response and anti-tumor effects	—

Countries

Japan

Contacts

Public ContactTakuro Wada

Sapporo Medical University Department of Orthopaedic Surgery

twada@sapmed.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026